Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27372303 | 0.78 | ALDH1A1 (0.52) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL21744257 | 0.78 | PIK3CD (0.43) | MEN1KMT2AKDM4ELMNAHTT | |
| SCHEMBL21743778 | 0.75 | PIK3CD (0.47) | MEN1KMT2AKDM4EMAPTMAPK1 | |
| SCHEMBL23619640 | 0.75 | ALDH1A1 (0.47) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL29865634 | 0.75 | KDM4E (0.51) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1011302 | 0.73 | NPC1 (0.52) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL21744609 | 0.73 | CYP2A13 (0.48) | MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL21743777 | 0.73 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL14863130 | 0.71 | CD44 (0.46) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL6174299 | 0.71 | ALDH1A1 (0.69) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | UNIV EMORY (US) | 2023-04-13 | — | — | US | disclosed |
| US-20200054623-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | EMORY UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054623-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | MEN1 4543/4885KMT2A 4253/4885ALDH1A1 1760/4885 |
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | MEN1 4543/4885KMT2A 4253/4885ALDH1A1 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.